Novartis buys Amblyotech to develop digital therapy for amblyopia
By Akshay Kedari  Date: 2020-04-21

Novartis buys Amblyotech to develop digital therapy for amblyopia

Novartis has recently made an announcement confirming that it has concluded its acquisition of Amblyotech, which is a software startup based in the U.S. Novartis will collaborate with McGill University and Ubisoft to be able to continue with the development of Amblyotech’s acquired digital tech for treating amblyopia, or “lazy eye”.

Apparently, there have been estimations regarding the amblyopia affecting about 3% of the world population. Some of these people can be appropriate candidates for the therapy when it gets approved. The condition generally results in poor vision and various other problems with the quality of life, if it is left untreated.

The condition is capable of impacting both adults and children beyond their vision that makes it difficult to both maintain and drive a sense of autonomy. There are various options for treatment currently, that include atropine and patching, which are mostly associated with a lower sense of compliance as well as a low rate of success. The adults have a limited set of approved therapies.

Reportedly, Amblyotech is aimed at improving compliance and it uses passive video and active gaming technology with 3D glasses, which trains the eyes for working together in order to view a complete image. The software employs a visual representation, which is called dichoptic display, wherein each eye is offered different images by using a proprietary algorithm.

The software of Amblyotech had shown big improvements in children as well as adults vision in the early clinical study as compared to the ones with standard care and treatment.

Global Business Franchise Head for Ophthalmology, Nikos Tripodis stated that the software of Amblyotech is an excellent example how the company can recreate medicines by using digital technology, as the firm offers a solution that is non-invasive and has the potential to be considerably faster than compared to the current care standards like patching for adults and children who have been impacted by lazy eye.

 

Source Credit- https://www.globenewswire.com/news-release/2020/04/20/2018335/0/en/Novartis-acquires-Amblyotech-pursuing-novel-digital-therapy-for-children-and-adult-patients-with-lazy-eye.html

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...

RADCOM introduces automated assurance solution for 5G technology
RADCOM introduces automated assurance solution for 5G technology
By Akshay Kedari

5G technology has been in the headlines for quite a while. Next-generation technology has the potential to transform almost every sector across the world. However, as 5G becomes reality, it has become imperative for service providers to prevent degra...

Sprout to expand wellness solutions lineup by acquiring Vivametrica
Sprout to expand wellness solutions lineup by acquiring Vivametrica
By Akshay Kedari

Sprout, a Canadian company that focuses on delivering innovative solutions for workplace wellbeing, has recently announced the acquisition of predictive health data analytics firm, Vivametrica. According to reliable sources, Sprout plans to enhance t...

Uber halts decision to shift APAC headquarters from Singapore
Uber halts decision to shift APAC headquarters from Singapore
By Akshay Kedari

Uber Technologies Inc., the American ride-hailing giant, has reportedly halted the company’s decision to relocate its Asia Pacific headquarters from Singapore to Hong Kong until December 2022. Sources cite that the company’s decision was...

PCI Pharma extends global clinical supply-chain services in Europe
PCI Pharma extends global clinical supply-chain services in Europe
By Akshay Kedari

U.S. based biopharmaceutical and pharma outsourcing services company, PCI Pharma services has reportedly announced that it reached a noteworthy milestone through the development of COE (Clinical Center of Excellence) in Berlin. According to credible...